0000899243-23-002183.txt : 20230119 0000899243-23-002183.hdr.sgml : 20230119 20230119171151 ACCESSION NUMBER: 0000899243-23-002183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230119 FILED AS OF DATE: 20230119 DATE AS OF CHANGE: 20230119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAILEY MICHAEL P CENTRAL INDEX KEY: 0001255856 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34655 FILM NUMBER: 23538150 BUSINESS ADDRESS: STREET 1: IMCLONE SYSTEMS INCORPORATED STREET 2: 180 VARICK STREET, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 6466385078 MAIL ADDRESS: STREET 1: IMCLONE SYSTEMS INCORPORATED STREET 2: 180 VARICK STREET, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001325879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043581650 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 30 WINTER STREET CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 857-400-0101 MAIL ADDRESS: STREET 1: 30 WINTER STREET CITY: BOSTON STATE: MA ZIP: 02108 FORMER COMPANY: FORMER CONFORMED NAME: AVEO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20050503 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-19 1 0001325879 AVEO PHARMACEUTICALS, INC. AVEO 0001255856 BAILEY MICHAEL P C/O AVEO PHARMACEUTICALS, INC. 30 WINTER STREET BOSTON MA 02108 1 1 0 0 President & CEO Common Stock 2023-01-19 4 D 0 333167 15.00 D 0 D Stock Option (Right to Buy) 77.20 2023-01-19 4 D 0 3249 D 2023-01-24 Common Stock 3249 0 D Stock Option (Right to Buy) 25.10 2023-01-19 4 D 0 11999 D 2023-06-26 Common Stock 11999 0 D Stock Option (Right to Buy) 17.70 2023-01-19 4 D 0 7499 D 2024-01-29 Common Stock 7499 0 D Stock Option (Right to Buy) 8.40 2023-01-19 4 D 0 90000 D 2025-01-06 Common Stock 90000 0 D Stock Option (Right to Buy) 10.80 2023-01-19 4 D 0 46000 D 2026-01-07 Common Stock 46000 0 D Stock Option (Right to Buy) 6.00 2023-01-19 4 D 0 75366 D 2027-02-07 Common Stock 75366 0 D Stock Option (Right to Buy) 30.80 2023-01-19 4 D 0 99999 D 2028-02-01 Common Stock 99999 0 D Stock Option (Right to Buy) 15.70 2023-01-19 4 D 0 16750 D 2024-06-19 Common Stock 16750 0 D Stock Option (Right to Buy) 6.20 2023-01-19 4 D 0 93500 D 2029-02-06 Common Stock 93500 0 D Stock Option (Right to Buy) 5.60 2023-01-19 4 D 0 35302 D 2030-02-05 Common Stock 35302 0 D Stock Option (Right to Buy) 9.12 2023-01-19 4 D 0 275100 D 2031-02-05 Common Stock 275100 0 D Stock Option (Right to Buy) 3.67 2023-01-19 4 D 0 625192 D 2032-02-15 Common Stock 625192 0 D Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration. This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration"). /s/ Danielle V. Holland, attorney in fact 2023-01-19